Publication portfolio

Research across the spectrum of neurodegeneration.

Biomarker discovery, systems biology, disease progression, metabolic comorbidity, lifestyle, and translational data science across Parkinson’s disease, Alzheimer’s disease, ALS, frontotemporal dementia, and atypical parkinsonian disorders.

Featured publications

Research highlights

Explore selected research, including our new Perspective in Med by Cell Press. Use the free-access link below to read the Perspective.

Med by Cell Press Perspective: Metabolic endotyping for mechanism-informed Alzheimer’s and Parkinson’s disease trials, with authors and affiliations

Featured publication · 2026

Med by Cell Press · Perspective

Metabolic endotyping for mechanism-informed Alzheimer’s and Parkinson’s disease trials

Santiago JA · Rascol O · Foltynie T · et al.

How metabolic endotyping could help identify patients most likely to benefit from metabolically targeted therapies and align trial outcomes with the mechanisms being targeted.

Free access to the Perspective
Cell Press ↗PubMed ↗
Trends in Molecular Medicine cover featuring a brain, blood biomarkers, DNA, and an injection device

Cover article · 2025

GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach

Trends in Molecular Medicine. A framework for integrating multimodal biomarkers into the development and evaluation of GLP-1 receptor agonists across neurodegenerative diseases.

Free access on PubMed ↗Cell Press ↗
Graphical overview of diabetes-related mechanisms contributing to ALS, Alzheimer’s disease, and Parkinson’s disease

Review · 2023

Diabetes: a tipping point in neurodegenerative diseases

Trends in Molecular Medicine. An analysis of convergent metabolic, vascular, inflammatory, and molecular mechanisms linking type 2 diabetes with neurodegenerative disease.

Read at Cell Press ↗DOI ↗
Article title and authors for A network approach to clinical intervention in neurodegenerative diseases Network analysis workflow connecting genomic evidence to candidate ranking and biomarker evaluation

Review · 2014

A network approach to clinical intervention in neurodegenerative diseases

Trends in Molecular Medicine. A network-based framework connecting genomic and molecular evidence with candidate prioritization, biomarker evaluation, and clinical translation.

Read at Cell Press ↗DOI ↗

Complete record

Peer-reviewed publications

  1. 2026
    Metabolic endotyping for mechanism-informed Alzheimer’s and Parkinson’s disease trialsMed · Cell Press · Perspective · doi:10.1016/j.medj.2026.101336
  2. 2026
    Baseline clinical features outperform structural MRI in predicting rapid cognitive and motor decline in Parkinson’s diseasenpj Parkinson’s Disease · In press
  3. 2023
    Diet and lifestyle impact the development and progression of Alzheimer’s dementiaFrontiers in Nutrition
  4. 2023
    Biological and clinical implications of sex-specific differences in Alzheimer’s diseaseHandbook of Experimental Pharmacology · Book chapter
  5. 2023
    Physical activity and lifestyle modifications in the treatment of neurodegenerative diseasesFrontiers in Aging Neuroscience
  6. 2023
    Coexpression network analysis identifies molecular determinants of loneliness associated with neuropsychiatric and neurodegenerative diseasesInternational Journal of Molecular Sciences
  7. 2022
    Sex-specific transcriptional rewiring in the brain of Alzheimer’s disease patientsFrontiers in Aging Neuroscience
  8. 2022
    Physical activity rewires the human brain against neurodegenerationInternational Journal of Molecular Sciences
  9. 2022
    Key disease mechanisms linked to amyotrophic lateral sclerosis in spinal cord motor neuronsFrontiers in Molecular Neuroscience
  10. 2021
    Transcriptomic and network meta-analysis of frontotemporal dementiasFrontiers in Molecular Neuroscience
  11. 2021
    Network analysis identifies sex-specific gene expression changes in blood of amyotrophic lateral sclerosis patientsInternational Journal of Molecular Sciences
  12. 2021
    The impact of disease comorbidities in Alzheimer’s diseaseFrontiers in Aging Neuroscience
  13. 2020
    Bioinformatic analysis reveals phosphodiesterase 4D-interacting protein as a key frontal cortex dementia switch geneInternational Journal of Molecular Sciences
  14. 2020
    Transcriptomic and network analysis identifies shared and unique pathways across dementia spectrum disordersInternational Journal of Molecular Sciences
  15. 2019
    Transcriptomic and network analysis highlight the association of diabetes at different stages of Alzheimer’s diseaseFrontiers in Neuroscience
  16. 2019
    Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer’s patientsPLOS ONE
  17. 2018
    PTPRC expression in blood is downregulated in Parkinson’s and progressive supranuclear palsy disordersJournal of Parkinson’s Disease
  18. 2018
    Evaluation of RNA blood biomarkers in the Parkinson’s Disease Biomarker ProgramFrontiers in Aging Neuroscience
  19. 2017
    Biological and clinical implications of comorbidities in Parkinson’s diseaseFrontiers in Aging Neuroscience
  20. 2017
    Evaluation of RNA blood biomarkers in individuals potentially at risk of Parkinson’s diseaseJournal of Parkinson’s Disease
  21. 2017
    Dissecting the molecular mechanisms of neurodegenerative diseases through network biologyFrontiers in Aging Neuroscience
  22. 2017
    Blood transcriptomic meta-analysis identifies dysregulation of hemoglobin and iron metabolism in Parkinson’s diseaseFrontiers in Aging Neuroscience
  23. 2016
    Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s diseaseScientific Reports
  24. 2015
    Blood biomarkers associated with cognitive decline in early-stage and drug-naive Parkinson’s disease patientsPLOS ONE
  25. 2015
    HNF4A and PTBP1 expression in the brain of neurodegenerative diseasesProceedings of the National Academy of Sciences
  26. 2015
    Blood biomarkers for Parkinson’s diseaseProceedings of the National Academy of Sciences
  27. 2015
    Network-based meta-analysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s diseaseProceedings of the National Academy of Sciences
  28. 2014
    A network approach to clinical intervention in neurodegenerative diseasesTrends in Molecular Medicine
  29. 2014
    Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson’s diseasePLOS ONE
  30. 2014
    Current challenges towards the development of a blood test for Parkinson’s diseaseDiagnostics
  31. 2014
    System-based approaches to decode the molecular links in Parkinson’s disease and diabetesNeurobiology of Disease
  32. 2014
    A network approach to diagnostic biomarkers in progressive supranuclear palsyMovement Disorders
  33. 2014
    The emerging role of nutrition in Parkinson’s diseaseFrontiers in Aging Neuroscience
  34. 2013
    Integrative network analysis unveils convergent molecular pathways in Parkinson’s disease and diabetesPLOS ONE
  35. 2013
    Shared dysregulated pathways lead to Parkinson’s disease and diabetesTrends in Molecular Medicine
  36. 2013
    Specific splice variants are associated with Parkinson’s diseaseMovement Disorders
  37. 2012
    Biosignatures for Parkinson’s disease and atypical parkinsonian disordersPLOS ONE

Evidence should lead to action.

NeuroHub brings publication-tested expertise to new datasets, biomarker programs, and translational research questions.

Explore services